boehringer glp-1 Boehringer, Zealand's MASH Data 'Unintentionally' Published by Medical Congress Website Boehringer, Zealand's GLP-1 MASH Data
Description
The rate of metabolic bariatric surgery decreased from 2022 to 2023, whereas the use of GLP-1 receptor agonists as anti-obesity medications grew over twofold, a research letter showed
This blog is part of an ongoing series on A Brave New World: Therapeutic Area Deep Dives
Inside the largest genetic study of GLP-1 response to date
That stability lines up with recent analyst debate around Q4 results, the updated 2026 outlook, and the role of LifeMD's GLP-1 focused virtual care program in shaping long term expectations
Do not start a GLP-1 receptor agonist in a patient with a prior diagnosis of gastroparesis
